- Home
- Plerimob 24Mg/1.2Ml Inj
Plerimob 24Mg/1.2Ml Inj Substitute
Plerimob 24Mg/1.2Ml Inj Substitute
Celstemx 24mg Injection
by Others
₹11890.00per tabletPlerixa 24 mg Injection 1.2 ml
by Others
₹21956.30per tabletMostim 24Mg/1.2Ml Inj
by AYUR
₹23054.70per tabletMozifer 1 Injection
by Others
₹32978.80per tabletPlerion 24 mg Injection 1.2 ml
by Others
₹45000.00per tabletCelrixafor Injection 1's
by Others
₹47153.30per tablet
Verified Ingredients and Effects
Composition:
PLERIXAFOR-24MG
Uses:
<p>Plerimob 24Mg/1.2Ml Inj is used in the treatment of Multiple Myeloma and Non-Hodgkin’s Disease. The detailed uses of Plerimob 24Mg/1.2Ml Inj are as follows:</p><ul><li><strong>Stem cell mobilization:</strong> Plerimob 24Mg/1.2Ml Inj is used in combination with granulocyte-colony stimulating factor (G-CSF) to help the bone marrow release hematopoietic stem cells into the bloodstream. These cells are then collected for autologous stem cell transplantation, a procedure often used in cancer treatment.</li><li><strong>Treatment of certain cancers:</strong> Plerimob 24Mg/1.2Ml Inj is indicated for patients with non-Hodgkin’s lymphoma and multiple myeloma who are undergoing stem cell transplantation. By increasing the number of stem cells in the blood, it improves the success rate of the transplant.</li></ul>
Medicinal Benefits:
Plerimob 24Mg/1.2Ml Inj contains Plerixafor, which belongs to the hemopoietic stem cell mobilizer class or drugs. It works by binding to the chemokine receptor CXCR4 and inhibiting its cognate ligand CXCL12 binding. This mobilizes hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in cancer patients.
FAQs
Plerimob 24Mg/1.2Ml Inj is used to treat Multiple Myeloma, Non-Hodgkin’s Disease.
Plerimob 24Mg/1.2Ml Inj contains Plerixafor, which works by binding to the chemokine receptor CXCR4 and inhibits the binding of its cognate ligand CXCL12.
Plerimob 24Mg/1.2Ml Inj may cause tumor cell mobilization and haematological effects such as increased lymphocytes, decreased platelet count, and splenic rupture in some patients. Hence, inform your oncologist about your complete medical history, including current medication, to rule out any side effects/interactions.
